PDS Biotech Corporation, a clinical-stage immunotherapy firm developing innovative cancer therapeutics based on its proprietary Versamune® T-cell activating technology, announced today that its executives would attend the Benzinga Healthcare Small-Cap Conference. management will update the three PDS0101 Phase 2 clinical trials that are currently underway. The presentation will also include an update on the progress of two investigational pipeline drugs, PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1), through human clinical trials.
Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech, will join a panel of prominent cancer experts to explore the future of oncology following the presentation. From September 29 to 30, 2021, the conference will be held virtually. PDS Biotech is a clinical-stage immunotherapy firm building a pipeline of cancer immunotherapies using its patented Versamune® T-cell activating technology platform.
flagship candidate, PDS0101, combines the Versamune® platform’s usefulness with targeted antigens in HPV-expressing tumors.is testing a combination of PDS0101 with KEYTRUDA® in Phase 2 research in recurrent or metastatic head and neck cancer. In addition, they collaborated with Merck & Co. PDS Biotech, the National Cancer Institute (NCI), and The University of Texas MD Anderson Cancer Center on two different Phase 2 studies in advanced HPV-associated malignancies and locally advanced cervical cancer.